Atyr Pharma Inc.

Company Overview

Business Model: aTyr Pharma, Inc. is a clinical stage biotechnology company focused on translating tRNA synthetase biology into new therapies for fibrosis and inflammation. The company's discovery platform aims to identify therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. Its lead therapeutic candidate is efzofitimod, a novel biologic immunomodulator in clinical development for interstitial lung disease (ILD).

Market Position: aTyr Pharma, Inc. is developing efzofitimod for ILD, a group of immune-mediated disorders with high unmet medical need and limited treatment options. Efzofitimod has received Orphan Drug Designations from the U.S. Food and Drug Administration (FDA) for the treatment of sarcoidosis and systemic sclerosis (SSc), and Fast Track designations for pulmonary sarcoidosis and SSc-ILD. The European Commission has also granted efzofitimod orphan drug designations for sarcoidosis and SSc. Kyorin Pharmaceutical Co., Ltd., aTyr Pharma, Inc.'s partner in Japan, has received orphan drug designation for efzofitimod for sarcoidosis from the Pharmaceutical and Medical Devices Agency (PMDA). The company believes efzofitimod is the most advanced drug candidate currently in development for pulmonary sarcoidosis.

Recent Strategic Developments:

• Phase 3 EFZO-FIT Study Results: In September 2025, aTyr Pharma, Inc. announced top-line data from its global Phase 3 EFZO-FIT study in patients with pulmonary sarcoidosis. The study, involving 268 patients, did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid (OCS) dose at week 48 (5.0 mg/kg efzofitimod reduced OCS to 2.79 mg vs. 3.52 mg for placebo, p=0.3313). However, the study demonstrated clinically meaningful improvements in the King’s Sarcoidosis Questionnaire (KSQ)-Lung score (p=0.0479) and a responder analysis for complete steroid withdrawal with an improved KSQ-Lung score (p=0.0196) for the 5.0 mg/kg efzofitimod dose compared to placebo. Additional pre-specified outcomes showed clinical improvements in Fatigue Assessment (FAS) Total Score (p=0.0226) and KSQ-General Health score (p=0.0197).
• Regulatory Pathway for Efzofitimod: A Type C meeting with the FDA is scheduled for mid-April 2026 to review the EFZO-FIT study results and determine the path forward for efzofitimod in pulmonary sarcoidosis.
• EFZO-CONNECT Study Progress: In June 2025, interim data from the Phase 2 EFZO-CONNECT study of efzofitimod in SSc-ILD patients showed clinically important improvement in modified Rodnan Skin Score (mRSS) assessment at 12 weeks in three out of four efzofitimod-treated diffuse SSc-ILD patients, with efzofitimod generally well-tolerated. Enrollment for this study is expected to complete in the first half of 2026.
• Pipeline Expansion: The company has advanced two new tRNA synthetase programs, ATYR0101 and ATYR0750, into preclinical development, focusing on fibrosis and inflammation.

Geographic Footprint: aTyr Pharma, Inc. conducts its operations primarily from its corporate headquarters and laboratory space in San Diego, California, United States. Clinical trials for efzofitimod have been conducted in the United States, Europe, Brazil, and Japan. The company has a 98% majority-owned subsidiary, Pangu BioPharma Limited, in Hong Kong and a collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod in Japan.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: Not meaningful due to minimal revenue.
• Operating Margin: Not meaningful due to minimal revenue.
• Net Margin: Not meaningful due to minimal revenue.

Investment in Growth:

• R&D Expenditure: $60.2 million (2025)
• Capital Expenditures: $0.077 million (2025)
• Strategic Investments: Not explicitly quantified as investments by aTyr Pharma, Inc. beyond R&D.

Business Segment Analysis

aTyr Pharma, Inc. operates in a single accounting segment, which includes all activities related to the discovery and development of its product candidates.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed for the year ended December 31, 2025.
• Dividend Payments: aTyr Pharma, Inc. has never declared or paid any cash dividends on its common stock.
• Dividend Yield: 0.0%
• Future Capital Return Commitments: The company does not intend to pay cash dividends on its common stock for the foreseeable future.

Balance Sheet Position (as of December 31, 2025):

• Cash and Equivalents: $10.7 million
• Total Debt: $0.9 million (primarily financing lease liabilities)
• Net Cash Position: $77.7 million (calculated as Cash and Equivalents + Available-for-sale investments - Total Debt)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Financing lease liabilities have a weighted-average remaining lease term of 1.2 years, with $0.676 million due in 2026 and $0.264 million in 2027.

Cash Flow Generation (for the year ended December 31, 2025):

• Operating Cash Flow: $(62.0) million
• Free Cash Flow: $(62.077) million (Operating Cash Flow less Capital Expenditures)
• Cash Conversion Metrics: Not explicitly disclosed.

Operational Excellence

Production & Service Model: aTyr Pharma, Inc. contracts with third parties for the manufacturing and testing of its product candidates, including efzofitimod, to support preclinical studies and clinical trials. The company does not own or operate manufacturing or testing facilities and has no current plans to build its own. It employs personnel to oversee these Contract Development and Manufacturing Organizations (CDMOs). Efzofitimod is a fusion protein expressed in recombinant E.coli.

Supply Chain Architecture: Key Suppliers & Partners:

• CDMOs: Engages CDMOs in the United States and internationally for the development and manufacture of drug substance and drug product under current Good Manufacturing Practices (cGMP). These CDMOs also handle labeling, storage, and distribution of drug product candidates to clinical sites.
• Manufacturing Updates: During 2023, a new CDMO completed its first and second full, commercial-scale bulk drug substance cGMP runs. In 2024, preparatory work began on three process performance qualification drug substance batches required for a potential Biologics License Application (BLA) submission for efzofitimod. In Q1 2025, the first upstream batch did not meet specifications and was replaced; the required three upstream batches were subsequently completed. In Q3 2025, the required three downstream batches were successfully completed, and the drug substance material was forward processed into drug product. Deviations were attributed to operational errors at the CDMO, not the underlying process or drug substance.
• CDMO Relocation: The company has been informed that its CDMO will be relocating the microbial manufacturing site used for prior batches and is assessing the impact of this transition.
• Supply Sufficiency: aTyr Pharma, Inc. believes it has sufficient efzofitimod on hand to meet projected needs for the EFZO-FIT-related Individual Patient EAP, the EFZO-CONNECT study, and a potential additional clinical study for efzofitimod in pulmonary sarcoidosis.

Facility Network:

• Manufacturing: Relies entirely on third-party CDMOs.
• Research & Development: Corporate headquarters and laboratory space located at 10240 Sorrento Valley Road, Suite 300, San Diego, California, comprising 24,866 rentable square feet.
• Distribution: Relies on third-party CDMOs.

Operational Metrics: Not explicitly disclosed beyond supply sufficiency statements.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: aTyr Pharma, Inc. intends to build the commercial infrastructure necessary to support the commercialization of its product candidates in the U.S. market, if and when regulatory approval appears imminent.
• Channel Partners: The company may elect to utilize strategic partners, distributors, or contract sales forces for commercialization in selected geographic locations or for particular indications.

Customer Portfolio: Strategic Partnerships:

• Kyorin Pharmaceutical Co., Ltd.: In January 2020, aTyr Pharma, Inc. entered into a collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILD in Japan. Kyorin received exclusive rights and is obligated to fund all research, development, regulatory, marketing, and commercialization activities in Japan. aTyr Pharma, Inc. is responsible for supplying drug product and supporting development activities. To date, the Kyorin Agreement has generated $20.0 million in upfront and milestone payments, with eligibility for up to an additional $155.0 million in development, regulatory, and sales milestones, plus tiered royalties on net sales in Japan.

Geographic Revenue Distribution:

• Japan: $0.2 million of collaboration revenue recognized in 2025 from product material sold to Kyorin Pharmaceutical Co., Ltd. to support analytical method validation.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biotechnology and pharmaceutical industries are intensely competitive and characterized by rapid and significant technological change. Competitors often possess substantially greater financial, technical, and other resources.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Pulmonary Sarcoidosis: Current standard of care includes glucocorticoids (FDA-approved in the 1950s), off-label immunosuppressive agents (e.g., methotrexate), and biologic immunomodulators (e.g., TNF inhibitors infliximab or adalimumab). aTyr Pharma, Inc. believes efzofitimod is the most advanced drug candidate in development for pulmonary sarcoidosis.
• Systemic Sclerosis-associated ILD (SSc-ILD): Treatment options include off-label immunosuppressive agents (mycophenolate mofetil, cyclophosphamide), Ofev (nintedanib) by Boehringer Ingelheim International GmbH (FDA approved 2019), and Actemra (tocilizumab) by F. Hoffmann-La Roche Ltd. and Chugai Pharmaceutical Co Ltd. (FDA approved 2021). Rituximab is also used off-label.
• General ILD: Other companies engaged in clinical development for ILD include Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Merck & Co., Sanofi-Aventis LLC, GSK plc, and United Therapeutics.

Emerging Competitive Threats: Not explicitly detailed beyond general industry competition and rapid technological change.

Competitive Response Strategy: aTyr Pharma, Inc. focuses on developing novel therapeutic approaches based on tRNA synthetase biology to address unmet medical needs, aiming for disease-modifying effects without the toxicity associated with current treatments.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Regulatory Pathway Uncertainty: There is no established FDA regulatory pathway for approval of a drug in pulmonary sarcoidosis. The EFZO-FIT study, which did not meet its primary endpoint, may not be sufficient for FDA approval and could require additional, costly clinical trials.
• Novel Therapeutic Approach: The company's focus on extracellular tRNA synthetase biology represents a novel therapeutic approach, which may lead to significant delays or may not result in commercially viable drugs.
• Public Perception: Public perception of safety issues related to new therapeutics or novel treatment approaches could influence clinical trial participation and physician adoption.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Supplier Dependency: Reliance on third-party CDMOs for manufacturing product candidates. Risks include inability to negotiate favorable agreements, reduced control over manufacturing, potential termination of agreements, and disruptions due to CDMO insolvency, natural disasters, labor shortages, economic slowdowns, or tariffs.
• Manufacturing Challenges: Experience with operational errors at CDMOs (e.g., Q1 2025 upstream batch failure) and potential delays due to contamination, equipment failure, or vendor error.
• CDMO Relocation: The current CDMO's planned relocation of its microbial manufacturing site could impact commercial supply planning and funding needs.
• Comparability Studies: Requirement to demonstrate comparability of product manufactured by new CDMOs to product used in prior clinical trials, which may involve additional nonclinical or clinical studies.

Financial & Regulatory Risks

Market & Financial Risks:

• Need for Additional Capital: aTyr Pharma, Inc. is a pre-commercial company with significant accumulated losses ($606.2 million as of December 31, 2025) and will require substantial additional funding to complete clinical trials, obtain regulatory approvals, and commercialize product candidates.
• Stock Price Volatility: The market price of the company's common stock has historically been highly volatile, and recent top-line data from the EFZO-FIT study has led to a material decline in stock price.
• Macroeconomic Conditions: Unfavorable macroeconomic conditions, including global geopolitical tension, armed conflicts, potential future health pandemics, banking system disruptions, tariffs, higher interest rates, and inflation, could adversely affect business, financial condition, and ability to raise capital.
• Liquidity: As of December 31, 2025, cash, cash equivalents, restricted cash, and available-for-sale investments totaled $80.9 million, believed to be sufficient for at least one year. Regulatory & Compliance Risks:
• Extensive Regulation: Subject to pervasive and continuing regulation by the FDA and other government authorities regarding manufacturing, development, marketing, and post-approval activities. Non-compliance can lead to sanctions, delays, or withdrawal of approvals.
• Orphan Drug Exclusivity: Orphan drug designation does not guarantee marketing exclusivity or prevent competitors from developing different products for the same indication or the same product for different indications.
• Expedited Review Programs: Fast Track designation does not guarantee expedited development, review, or approval.
• FDA Disruptions: Layoffs, funding shortages, or other disruptions at the FDA and other government agencies could negatively impact regulatory review and approval timelines.

Geopolitical & External Risks

Geographic Dependencies:

• International Operations: Risks associated with conducting research and clinical trials in foreign countries (e.g., Hong Kong, EU, Brazil, Japan, Australia), including differing regulatory requirements, foreign exchange fluctuations, customs, cultural differences, political instability, and diminished intellectual property protection.
• Trade Relations: International trade policies, including tariffs and trade barriers, could affect the availability and cost of raw materials and impact business.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• tRNA Synthetase Biology: Focused on extracellular functions of tRNA synthetase biology, a newly discovered area.
• Efzofitimod (HARS-derived): A novel immunomodulatory Fc fusion protein that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation and potentially prevent fibrosis.
• ATYR0101 (DARS-derived): A fusion protein derived from aspartyl-tRNA synthetase (DARS), engineered with a human Fc region. It selectively eliminates activated myofibroblasts by targeting Latent TGF-β Binding Protein-1 (LTBP-1) within the extracellular matrix (ECM), inducing apoptosis in a TGF-β dependent manner. Preclinical studies show antifibrotic effects in lung and kidney fibrosis models.
• ATYR0750 (AARS-derived): A fusion protein derived from alanyl-tRNA synthetase (AARS), identified as a novel ligand to fibroblast growth factor receptor 4 (FGFR4), which is involved in inflammation and fibrosis, particularly in the liver.

Innovation Pipeline:

• Efzofitimod: In clinical development for ILD, with potential applications in chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD (CTD-ILD), including SSc-ILD and rheumatoid arthritis-associated ILD.
• ATYR0101 & ATYR0750: In preclinical development, with plans for further mechanistic investigations and in vitro/in vivo preclinical studies.

Intellectual Property Portfolio:

• Patent Strategy: Owns or exclusively licenses a broad array of patents and allowed patent applications covering human tRNA synthetase biology, their receptors, and associated signaling pathways. Plans to expand by filing patent applications for new methods of treatment, therapeutics, and next-generation product forms.
• Efzofitimod IP: Patent families related to HARS derivatives, splice variants, combinations with other therapeutics, and next-generation product forms. Jointly owned with Pangu BioPharma Limited. U.S. patents are expected to expire between 2030 and 2031 (with potential extensions to 2039). Ex-U.S. patents are expected to expire in 2030 (with potential extensions).
• tRNA Synthetases IP: Patent families covering all 20 human cytosolic tRNA synthetases, including issued U.S. patents for specific therapeutic protein compositions and antibody compositions. Patents from these applications are expected to expire between 2026 and 2045 (with potential extensions).
• Licensing Programs: Not explicitly detailed as a revenue-generating program beyond the Kyorin Pharmaceutical Co., Ltd. agreement.

Technology Partnerships:

• Research Collaborations: Collaborates with the Hong Kong University of Science and Technology for certain research activities.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: Not explicitly detailed in the filing.

Board Composition (as of March 5, 2026):

• Chairman of the Board: Timothy P. Coughlin
• Directors: Eric Benevich, Jane A. Gross, Ph.D., Svetlana Lucas, Ph.D., Paul Schimmel, Ph.D., Sara L. Zaknoen, M.D.
• Independence, expertise areas, committee structure: Not explicitly detailed in the filing.

Human Capital Strategy

Workforce Composition (as of December 31, 2025):

• Total Employees: 58 employees (56 full-time).
• Geographic Distribution: All employees are based in the United States.
• Skill Mix: 35 employees are in research and development, clinical, manufacturing, and regulatory affairs roles; 21 employees are in general and administrative capacities.

Talent Management: Acquisition & Retention:

• Hiring Strategy: Attracting, developing, and retaining talented employees is crucial for executing the company's strategy.
• Retention Metrics: Not explicitly disclosed.
• Employee Value Proposition: Investments are made in employees to be an employer of choice, considering compensation, benefits, talent development, career opportunities, and work environment.

Diversity & Development:

• Development Programs: Employees are required to complete training in various safety procedures for laboratories and manufacturing facilities, with specialized training based on job duties.
• Culture & Engagement: The company's Code of Business Conduct and Ethics emphasizes core values of respect, integrity, collaboration, innovation, trust, and excellence.

Environmental & Social Impact

Environmental Commitments: Not explicitly detailed in the filing.

Supply Chain Sustainability: Not explicitly detailed in the filing.

Social Impact Initiatives: Not explicitly detailed in the filing.

Business Cyclicality & Seasonality

Demand Patterns: Not explicitly detailed in the filing.

Planning & Forecasting: Not explicitly detailed in the filing.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• U.S. Regulation: Subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act. This includes requirements for preclinical testing (Good Laboratory Practice), clinical trials (Investigational New Drug application, Institutional Review Board approval, Good Clinical Practice), Biologics License Application (BLA) submission, pre-approval inspections (cGMP), and post-approval monitoring (recordkeeping, adverse event reporting, advertising, and promotion).
• International Compliance: Subject to regulations in other jurisdictions, including the European Union (Clinical Trial Authorization application, European Medicines Agency, Committee for Orphan Medicinal Products) and Japan (Pharmaceutical and Medical Devices Agency).
• Expedited Programs: Has received Fast Track designations for efzofitimod for pulmonary sarcoidosis and SSc-ILD, and Orphan Drug Designations for sarcoidosis and SSc.

Trade & Export Controls: Not explicitly detailed in the filing beyond general international trade policies and tariffs as risk factors.

Legal Proceedings:

• Securities Class Action Complaints: On October 9, 2025, and October 22, 2025, two substantially similar putative securities class action complaints were filed in the U.S. District Court for the Southern District of California, naming aTyr Pharma, Inc. and its Chief Executive Officer, Sanjay Shukla. The complaints allege violations of Section 10(b) of the Exchange Act and SEC Rule 10b-5, and Section 20(a) of the Exchange Act against Mr. Shukla, related to allegedly false or misleading statements concerning efzofitimod. The court consolidated the cases and appointed co-lead plaintiffs on February 9, 2026. The company believes it has meritorious defenses and intends to vigorously defend the matter.

Tax Strategy & Considerations

Tax Profile (as of December 31, 2025):

• Effective Tax Rate: 0.0% due to a full valuation allowance against deferred tax assets.
• Geographic Tax Planning: Pretax losses for 2025 were primarily from U.S. operations ($73.9 million) and foreign operations ($0.2 million).
• Tax Reform Impact: Federal Net Operating Losses (NOLs) incurred after December 31, 2017, can be carried forward indefinitely but are limited to 80% of taxable income. California state NOLs are subject to limitations for tax years beginning after 2023 and before 2027.
• NOL Carryforwards: Federal NOLs of approximately $347.7 million (with $235.3 million carrying forward indefinitely and $112.4 million expiring between 2026 and 2037). State NOLs of approximately $298.6 million (with $177.9 million carrying forward indefinitely and $120.7 million expiring between 2026 and 2045). Foreign NOLs of approximately $9.6 million carry forward indefinitely.
• Tax Credit Carryforwards: Federal R&D credits of approximately $12.7 million and state R&D credits of approximately $6.9 million, both beginning to expire in 2026. Federal Orphan Drug Credits of $26.7 million, beginning to expire in 2035.
• Section 382 Limitations: Utilization of NOL and credit carryforwards may be subject to annual limitations due to past or future ownership changes under Section 382 of the Internal Revenue Code.
• Unrecognized Tax Benefits: Totaled $42.8 million as of December 31, 2025.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: aTyr Pharma, Inc. maintains product liability insurance for its clinical trials, with coverage of $10.0 million per occurrence and up to $10.0 million in the aggregate. The company intends to expand this coverage upon obtaining marketing approval for product candidates to include commercial sales.
• Risk Transfer Mechanisms: Not explicitly detailed in the filing.